MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
Strategic location tips for playgroups and education centres
Innovating CSDs: What Hong Kong can learn from Euroclear Cash+
How student hostels conversion projects can qualify as social loans